Patent foramen ovale interventions: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Percutaneous closure, antiplatelets or anticoagulants may be used in preventing recurrent strokes in patients with patent foramen ovale | Percutaneous closure, antiplatelets or [[anticoagulants]] may be used in preventing recurrent [[Stroke|strokes]] in patients with patent foramen ovale | ||
==Indications== | ==Indications== | ||
*The treatment options available to prevent recurrent stroke in patent foramen ovale patients include:<ref name="KuijpersSpencer2018">{{cite journal|last1=Kuijpers|first1=Ton|last2=Spencer|first2=Frederick A|last3=Siemieniuk|first3=Reed A C|last4=Vandvik|first4=Per O|last5=Otto|first5=Catherine M|last6=Lytvyn|first6=Lyubov|last7=Mir|first7=Hassan|last8=Jin|first8=Albert Y|last9=Manja|first9=Veena|last10=Karthikeyan|first10=Ganesan|last11=Hoendermis|first11=Elke|last12=Martin|first12=Janet|last13=Carballo|first13=Sebastian|last14=O’Donnell|first14=Martin|last15=Vartdal|first15=Trond|last16=Baxter|first16=Christine|last17=Patrick-Lake|first17=Bray|last18=Scott|first18=Joanie|last19=Agoritsas|first19=Thomas|last20=Guyatt|first20=Gordon|title=Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline|journal=BMJ|year=2018|pages=k2515|issn=0959-8138|doi=10.1136/bmj.k2515}}</ref> | *The treatment options available to prevent recurrent [[stroke]] in patent foramen ovale patients include:<ref name="KuijpersSpencer2018">{{cite journal|last1=Kuijpers|first1=Ton|last2=Spencer|first2=Frederick A|last3=Siemieniuk|first3=Reed A C|last4=Vandvik|first4=Per O|last5=Otto|first5=Catherine M|last6=Lytvyn|first6=Lyubov|last7=Mir|first7=Hassan|last8=Jin|first8=Albert Y|last9=Manja|first9=Veena|last10=Karthikeyan|first10=Ganesan|last11=Hoendermis|first11=Elke|last12=Martin|first12=Janet|last13=Carballo|first13=Sebastian|last14=O’Donnell|first14=Martin|last15=Vartdal|first15=Trond|last16=Baxter|first16=Christine|last17=Patrick-Lake|first17=Bray|last18=Scott|first18=Joanie|last19=Agoritsas|first19=Thomas|last20=Guyatt|first20=Gordon|title=Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline|journal=BMJ|year=2018|pages=k2515|issn=0959-8138|doi=10.1136/bmj.k2515}}</ref> | ||
:*Percutaneous closure | :*Percutaneous closure | ||
:*Antiplatelet therapy | :*Antiplatelet therapy | ||
:*Anticoagulant therapy | :*[[Anticoagulant]] therapy | ||
==References== | ==References== | ||
Latest revision as of 02:50, 17 February 2020
|
Patent Foramen Ovale Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Patent foramen ovale interventions On the Web |
|
American Roentgen Ray Society Images of Patent foramen ovale interventions |
|
Risk calculators and risk factors for Patent foramen ovale interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2]
Overview
Percutaneous closure, antiplatelets or anticoagulants may be used in preventing recurrent strokes in patients with patent foramen ovale
Indications
- The treatment options available to prevent recurrent stroke in patent foramen ovale patients include:[1]
- Percutaneous closure
- Antiplatelet therapy
- Anticoagulant therapy
References
- ↑ Kuijpers, Ton; Spencer, Frederick A; Siemieniuk, Reed A C; Vandvik, Per O; Otto, Catherine M; Lytvyn, Lyubov; Mir, Hassan; Jin, Albert Y; Manja, Veena; Karthikeyan, Ganesan; Hoendermis, Elke; Martin, Janet; Carballo, Sebastian; O’Donnell, Martin; Vartdal, Trond; Baxter, Christine; Patrick-Lake, Bray; Scott, Joanie; Agoritsas, Thomas; Guyatt, Gordon (2018). "Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline". BMJ: k2515. doi:10.1136/bmj.k2515. ISSN 0959-8138.